CRO Charles River Laboratories has selected Exostar to serve as the gatekeeper to its data, tasking the cloud-based service provider with securing its proprietary information.
Charles River Laboratories is kicking off an all-encompassing service that will allow its biotech and pharma clients to hand over their quality-control testing for biologics en masse, a method the preclinical CRO says can save time and money.
Charles River Laboratories has pulled off a sweeping reorganization over the past few years, and the effort returned the preclinical CRO to revenue growth in 2013, setting the stage for another jump this year.
Preclinical CRO Charles River Laboratories is shuffling its high offices in an effort to better focus on efficiency, uniting its business units to slash spending and speed up growth.
Charles River Laboratories has convinced the CEO of Memorial Sloan-Kettering Cancer Center to join its board of directors, leading a new committee to ensure the CRO stays on the cutting edge of science.
Despite ongoing slowness in the market for early-stage research, preclinical specialist Charles River Laboratories boosted its revenue and income in the third quarter, a credit to its continued cost cuts and gains in market share, the company said.
Theorem Clinical Research has struck a deal with Charles River Laboratories, adding the early-phase-focused CRO's capabilities to its drug development platform.
They don't make compounds like the used to--or at least at the same rate. And with fewer and fewer early-stage molecules moving through pipelines, some discovery-focused CROs have been left in the lurch.
Preclinical specialist Charles River Labs posted solid revenue growth despite a tough market for early-phase services, but a spike in charges pulled down net income on an otherwise strong second quarter.
Charles River Labs saw its net profits decline about 2.3% last quarter, as risings costs negated 1.8% revenue growth.